KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Other Non-Current Assets data on record, last reported at $57.8 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 3.87% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $57.8 million, down 3.87%, while the annual FY2025 figure was $57.8 million, 3.87% down from the prior year.
  • Other Non-Current Assets reached $57.8 million in Q4 2025 per AMRX's latest filing, up from $45.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $108.3 million in Q3 2022 and bottomed at $19.2 million in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $58.5 million, with a median of $57.8 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Assets: soared 454.39% in 2022, then plummeted 59.26% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $20.6 million in 2021, then skyrocketed by 400.71% to $103.2 million in 2022, then crashed by 46.21% to $55.5 million in 2023, then rose by 8.31% to $60.1 million in 2024, then dropped by 3.87% to $57.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $57.8 million in Q4 2025, $45.4 million in Q1 2025, and $60.1 million in Q4 2024.